Your session is about to expire
← Back to Search
Ubrogepant for Migraine (UNION Trial)
UNION Trial Summary
This trial is comparing the effectiveness of two different doses of ubrogepant, a medication used to treat migraines, in patients who are also being treated with or without injectable CGRPmAbs (another medication used to treat migraines). The trial will involve patients recording information about their migraine symptoms and treatment response, and will compare the safety data with the original clinical trial.
UNION Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.UNION Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I experience 3 or more days of moderate to severe headaches each month.You have used illegal drugs or had a problem with drugs or alcohol in the past year.I am currently receiving Botox for chronic migraines.I am currently using gepants to prevent my condition.My serious health conditions have been stable for over a year and won't affect my study participation.My migraines usually last 4-72 hours and I have pain-free periods of at least 48 hours between them.I am not taking strong medications like ketoconazole.I have been on CGRP inhibitor treatment for more than a month.I am between 18 and 75 years old.I have had migraines for at least a year.I experience less than 3 moderate to severe headaches a month.I am not taking medications like phenytoin or St. John's Wort.
- Group 1: w/o CGRPmAb
- Group 2: Tx w/ CGRPmAb
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary objectives of this research endeavor?
"This experiment, which will be evaluated two hours after the intervention is applied, seeks to determine Freedom from most bothersome symptom. Secondary goals include gauging Percentage of patients with sustained pain relief from 2-24 hours post second dose., Percentage of patients with sustained pain freedom over a similar time range, and Pain relief at 2 hours (not necessarily total abatement)."
Is the enrollment window currently available for prospective participants?
"Contrary to what is posted on clinicaltrials.gov, this investigation has concluded its search for participants; the study was initially shared August 1st 2022 and last updated August 14th 2022. While no longer recruiting patients, there are still 260 other trials that require volunteers at present."
Is my involvement in this experiment possible?
"This medical trial seeks 164 applicants who suffer from frequent headaches/migraines and are 18-75 years old."
How secure are the outcomes of treatment with CGRPmAb for individuals?
"There is ample evidence supporting the safety of Tx w/ CGRPmAb, thus it received a rating of 3 on our scale. This medication has already gone through Phase 4 trials and been approved for use."
Are elderly individuals eligible to participate in this experiment?
"To be considered for this trial, one must fall between 18 and 75 years old. Moreover, there are 43 seperate clinical trials catering to patients younger than 18 as well as 178 studies aimed towards those over 65."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger